Extended TARPEYO treatment for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether taking TARPEYO (budesonide) for longer than 9 months is safe and effective for adults with IgA nephropathy. It's for people who have already completed a 9-month course of TARPEYO and are on stable blood pressure medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have IgA nephropathy confirmed by a kidney biopsy.
- You must be at least 18 years old.
- You must have completed a full 9-month course of TARPEYO (budesonide) treatment.
- You must have stable lab results (urine protein and creatinine levels) from before starting TARPEYO.
- You must be on a stable dose of blood pressure medication (ACE inhibitor, ARB, or sparsentan) for at least 8 weeks.
- You cannot have other kidney diseases or conditions like dialysis, transplant, or poorly controlled diabetes/hypertension.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests telitacicept in people with IgA nephropathy that has not responded well to standard care. It aims to reduce harmful kidney inflammation and protein leakage in the urine.
This trial tests whether a new medicine called finerenone can help people with IgA nephropathy, a kidney disease. You may be able to join if you are already on blood pressure medications, your kidney function is at a certain level, and you haven't needed immune-suppressing drugs recently.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This trial is collecting real-world information from people with IgA nephropathy who are taking the medications iptacopan or atrasentan. The goal is to better understand how these treatments work in everyday medical practice.
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.